RenalRheumatology
Lupus Nephritis
Class III/IV (proliferative) and class V (membranous) — induction with MMF or cyclophosphamide, maintenance, hydroxychloroquine, belimumab/voclosporin.
Source: EULAR/ERA-EDTA 2019; KDIGO 2024
Step 1 of ~6
info
Recognise + Biopsy
Lupus + new proteinuria (≥0.5 g/day) ± haematuria ± AKI. Bloods: ANA, anti-dsDNA, complement (C3/C4 ↓), ESR ↑, CRP often normal or modestly raised, anti-Sm, antiphospholipid antibodies. Renal biopsy mandatory — Class I (minimal mesangial), II (mesangial proliferative), III (focal proliferative), IV (diffuse proliferative — most severe), V (membranous), VI (advanced sclerosing).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Cyclophosphamide (Nephrology) · ANCA Vasculitis / Lupus Nephritis
- Belimumab (Lupus Nephritis) · Lupus Nephritis
- Voclosporin · Lupus Nephritis
- Voclosporin (Calcineurin Inhibitor — Lupus Nephritis) · Calcineurin Inhibitor (CNI) — Cyclosporin Analogue
- Lidocaine hydrochloride · Amide local anaesthetic / Class IB antiarrhythmic
- Hydroxychloroquine · Antimalarial — Lupus / Dermatoses
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.